Lecirelin Injection

Pain is a common accompanying symptom of many diseases, which seriously affects the quality of life of patients. Relieve pain through multiple unique and interrelated mechanisms, especially suitable for the following different types of pain situations.

Neuropathic pain: Neuropathic pain is a kind of pain caused by nervous system injury or disease. Common diseases include diabetes peripheral neuropathy, post herpetic neuralgia, etc. In diabetes peripheral neuropathy, long-term hyperglycemia will lead to neural microvascular disease, resulting in nerve ischemia, hypoxia, and then nerve damage. This type of injury can cause changes in the expression and activity of nerve growth factor (NGF). It can accurately block the activity of nerve growth factor (NGF) and reduce abnormal excitation of neurons from the source.

After a decrease in neuronal excitability, the generation and transmission of pain signals are significantly inhibited. For example, in patients with postherpetic neuralgia, virus invasion of nerve nodes can cause inflammation and damage to the nerves, leading to excessive excitation of neurons and sustained pain. By regulating the excitability of neurons, this stubborn pain has been effectively alleviated, bringing significant pain relief effects to patients and improving their quality of life.
Tumor related pain: Tumor related pain is one of the common symptoms in cancer patients, among which pain caused by bone metastasis is particularly common and severe. When tumor cells metastasize to the bone, they stimulate the activity of osteoclasts, leading to their excessive proliferation and activation.

Osteoclasts secrete acidic substances and proteases to dissolve bone matrix, leading to increased bone resorption, disrupting the normal structure and stability of bones, and causing severe bone pain. It can specifically inhibit the activity of osteoclasts and reduce the process of bone resorption. It reduces bone pain by regulating signaling pathways within osteoclasts, inhibiting their differentiation and maturation, and decreasing their activity. In cancer patients prone to bone metastasis such as breast cancer and prostate cancer, the application significantly alleviates the symptoms of bone pain, reduces the dependence of patients on pain relievers, and improves the quality of life of patients.

Visceral pain: Visceral pain is pain caused by stimulation or damage to internal organs, commonly seen in diseases such as pancreatitis and irritable bowel syndrome.

In pancreatitis, inflammatory stimulation can lead to edema, bleeding, and necrosis of pancreatic tissue, causing stimulation of nerve endings around the pancreas and resulting in visceral spasmodic pain. Irritable bowel syndrome is a functional gastrointestinal disorder in which the patient's intestinal motility and secretion function are disrupted, leading to intestinal spasms and pain. It can inhibit the peristalsis and secretion of the gastrointestinal tract, alleviate visceral spasmodic pain by regulating the contraction and relaxation of smooth muscles in the gastrointestinal tract. It acts on the nerve endings and smooth muscle cells in the gastrointestinal tract, inhibiting the release of neurotransmitters and muscle contraction, thereby relieving pain symptoms. In clinical applications, many patients with pancreatitis and irritable bowel syndrome have shown significant improvement in pain symptoms and quality of life after using ranitidine acetate.

Chemotherapy, radiotherapy, or postoperative nausea and vomiting (CINV/PONV) are common adverse reactions in clinical treatment, seriously affecting patients' treatment compliance and quality of life. These treatment methods can stimulate the gastrointestinal mucosa, leading to a large release of serotonin (5-HT). 5-HT is an important neurotransmitter that activates 5-HT3 receptors to transmit signals of nausea and vomiting to the central nervous system, triggering the vomiting reflex. It can inhibit the release of 5-HT and reduce its content in the gastrointestinal mucosa, thereby reducing the activation effect of 5-HT on 5-HT3 receptors. At the same time, it can directly block 5-HT3 receptors, further blocking the transmission of nausea and vomiting signals. In chemotherapy patients, early use of lecirelin injection can significantly reduce the frequency and severity of nausea and vomiting, improve patients' tolerance to chemotherapy, and enable them to better complete the chemotherapy course.

When used at low doses, it exhibits a unique effect of promoting gastric emptying and small intestinal peristalsis. Functional dyspepsia and gastroparesis are common digestive system diseases, and patients often experience symptoms such as upper abdominal fullness, early satiety, belching, nausea, etc., which seriously affect eating and digestive function. The occurrence of these diseases is closely related to insufficient gastrointestinal motility. Acetate lanrelitide enhances the peristalsis ability of the stomach and small intestine by regulating the neural regulation and muscle contraction of the gastrointestinal tract, promoting food digestion and emptying. It acts on smooth muscle cells in the gastrointestinal tract, increasing the concentration of intracellular calcium ions, promoting muscle contraction, and thus improving gastrointestinal motility. In patients with functional dyspepsia and gastroparesis, treatment with low-dose lanrelitide acetate resulted in significant improvement in symptoms and recovery of digestive function.

Inflammatory bowel disease (IBD) is a group of chronic non-specific intestinal inflammatory diseases, including ulcerative colitis and Crohn's disease. Its pathogenesis is related to factors such as abnormal activation of the intestinal immune system and increased release of pro-inflammatory cytokines. TNF - α, IL-6 and other pro-inflammatory cytokines play a key role in the pathogenesis of IBD. They can activate immune cells in the intestine, trigger inflammatory reactions, and lead to intestinal mucosal damage and ulcer formation. It can inhibit the release of pro-inflammatory cytokines in the intestine, reduce the production of cytokines such as TNF - α and IL-6 by regulating the activity and signaling pathways of immune cells. In both animal experiments and clinical studies, it has been found that the use of lanreotide acetate significantly reduces intestinal inflammation in IBD patients, repairs intestinal mucosal damage, and improves clinical symptoms. This provides new ideas and methods for the treatment of IBD.